Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Wistar Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Wistar Institute, Medical Devices Deals, 2012 to YTD 2018 10
The Wistar Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
The Wistar Institute, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Wistar Institute and Harbour BioMed Enter into Research Agreement 12
Innate Biologics Enters into Research Agreement with Wistar Institute 13
Helen F. Graham Cancer Center & Research Institute Enters into Agreement with Wistar Institute 14
Inovio Pharma Enters into Research Agreement with Wistar Institute 15
PhoreMost Enters into Agreement with Wistar Institute 16
Wistar Institute Into Agreement with Fox Chase Chemical Diversity 17
Licensing Agreements 18
ITUS Enters into Licensing Agreement with Wistar Institute 18
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 19
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 20
Asset Transactions 21
PepVax Acquires Rights from Wistar Institute 21
The Wistar Institute – Key Competitors 22
The Wistar Institute – Key Employees 23
The Wistar Institute – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Government and Public Interest 25
Sep 27, 2018: Targeting multiple members of a family of tumor antigens with a synthetic DNA vaccine shows promise for cancer immunotherapy 25
Sep 05, 2018: Enhancing the Efficacy of Immune Checkpoint Inhibitor Therapy Using a Novel Treatment Combination 26
Jun 13, 2018: Older Melanoma Patients Have Better Response to Immune Checkpoint Blockade Therapy 27
May 30, 2018: Wistar Receives Grant from the Jayne Koskinas Ted Giovanis Foundation for Health and Policy to Support the Breast Cancer Research Consortium 28
Mar 27, 2018: Repurposing Existing FDA-Approved Inhibitors May Provide New Treatment Approach for Ovarian Cancer 29
Mar 21, 2018: Targeting Telomeres to Overcome Therapy Resistance in Advanced Melanoma 30
Feb 12, 2018: Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria 31
Jan 29, 2018: Science Center’s QED Program Awards $600,000 to Advance the Commercialization of Three University Technologies Awards Given to New Jersey Institute of Technology, Temple University and The Wistar Institute 32
Jan 18, 2018: The Wistar Institute Awarded More Than $1.4 Million to Create a Malaria Vaccine Through Synthetic DNA-Based Technology 34
Dec 14, 2017: Wistar Scientists Identify Mechanism of Impaired Dendritic Cell Function that Weakens Immune and Therapeutic Response to Cancer 35
Nov 15, 2017: Wistar Science Highlights: New Research In Melanoma And Cancer Immunotherapy 36
Nov 06, 2017: The Wistar Institute Awarded More Than $16.5M in Grants to Fund Cancer & Infectious Disease Research and Training 37
Sep 27, 2017: Melanoma Cells Rewire Their Signaling Pathways to Resist Drug Treatment 39
Sep 19, 2017: Tumor-infiltrating B Lymphocytes Promote Melanoma Progression and Resistance to Therapy 40
Sep 11, 2017: Modulating T-Cell Metabolism Uncovers New Technology for Enhancing Immunotherapy 41
Aug 17, 2017: Wistar Scientists Develop Novel Immunotherapy Technology for Prostate Cancer 42
Jul 24, 2017: New Therapeutic Approach for Difficult-to-Treat Subtype of Ovarian Cancer Identified 43
Jul 13, 2017: Wistar Science Highlights: A More Effective Flu Vaccine Design, New Drug Boosts Antitumor Effects, Awards For Melanoma Research 44
Jul 06, 2017: New Synthetic DNA-Based Strategy Shows Promise Against a Diverse Range of Influenza Viruses 45
Apr 24, 2017: Wistar Scientists Discover New Function for ADAR1 in Protecting Stressed Cells from Apoptotic Death 46
Mar 13, 2017: Wistar Research Teams Awarded More Than $4.7 Million in Funding 47
Mar 03, 2017: Wistar’S Qihong Huang, M.D., Ph.D., Receives $50K Grant From The PA Breast Cancer Coalition For Novel Therapeutic Approach For Metastatic Breast Cancer 48
Feb 23, 2017: Anti-Aging Gene Identified as a Novel Promising Therapeutic Target for Older Melanoma Patients 49
Product News 50
Dec 19, 2017: Novel Combination Therapy Shown to Be Effective in Ovarian 50
Sep 20, 2017: Characterization of a Slowly Proliferating Population of Melanoma Cells with High Metastatic Properties 51
Apr 25, 2018: Targeting Telomerase as a Therapeutic Strategy for Difficult-to-Treat Melanoma 52
Jan 11, 2017: The Wistar Institute and Nation’s Cancer Centers Jointly Endorse Updated HPV Vaccine Recommendations 53
Appendix 54
Methodology 54
About GlobalData 54
Contact Us 54
Disclaimer 54
The Wistar Institute, Pharmaceuticals & Healthcare, Key Facts 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Wistar Institute, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Wistar Institute, Deals By Therapy Area, 2012 to YTD 2018 9
The Wistar Institute, Medical Devices Deals, 2012 to YTD 2018 10
The Wistar Institute, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Wistar Institute and Harbour BioMed Enter into Research Agreement 12
Innate Biologics Enters into Research Agreement with Wistar Institute 13
Helen F. Graham Cancer Center & Research Institute Enters into Agreement with Wistar Institute 14
Inovio Pharma Enters into Research Agreement with Wistar Institute 15
PhoreMost Enters into Agreement with Wistar Institute 16
Wistar Institute Into Agreement with Fox Chase Chemical Diversity 17
ITUS Enters into Licensing Agreement with Wistar Institute 18
Horizon Discovery Enters into Licensing Agreement with Wistar Institute 19
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 20
PepVax Acquires Rights from Wistar Institute 21
The Wistar Institute, Key Competitors 22
The Wistar Institute, Key Employees 23
List of Figures
The Wistar Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
The Wistar Institute, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
The Wistar Institute, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
The Wistar Institute, Medical Devices Deals, 2012 to YTD 2018 10